Saracatinib in Treating Patients With Locally Advanced or Metastatic Stomach or Gastroesophageal Junction Cancer

NCT00607594 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

21

Enrollment

NIH

Sponsor class

Conditions

Adenocarcinoma of the Gastroesophageal Junction
Adenocarcinoma of the Stomach
Recurrent Gastric Cancer
Stage III Gastric Cancer
Stage III Esophageal Cancer
Stage IV Esophageal Cancer
Stage IV Gastric Cancer

Interventions

DRUG: saracatinib

Sponsor

National Cancer Institute (NCI)